

Case Report of Castration-Resistant Prostate Cancer with Metastasis to the External Auditory Canal

Naoki Akagi*

Department of Urology, Takarazuka City Hospital, Japan

Abstract

A case of castration-resistant prostate cancer metastasis to an external auditory canal is described. Prostate cancer (cT3aN1M1b GS5+5) was discovered in a 68-year-old man. Despite the fact that abiraterone, docetaxel,

Introduction

A 68-year-old man was referred to our hospital for examination and treatment after visiting a local doctor for gross hematuria. A rectal examination revealed stony hardness and a PSA level of 84 ng/ml, so a transperineal prostate biopsy was performed, and the results revealed adenocarcinoma, GS 5 + 5 = 10. Furthermore, contrast-enhanced computed tomography (CT) revealed metastasis in the pararenal aorta, common iliac, and left external iliac lymph nodes, as well as metastasis in the left iliac and vertebrae. As a result, the patient was diagnosed with prostate cancer, cT3aN1M1b, and treatment options were discussed. We began treatment with abiraterone and degarelix. The lowest prostate-specific antigen (PSA) level was 1.9 ng/ml during the first three months of treatment, but four months later, that level was found to be elevated, indicating disease progression. Testosterone levels were low, and castration-resistant prostate cancer was discovered. After starting docetaxel, PSA dropped from 2.6 to 0.37 ng/ml. Following that, PSA gradually increased, though imaging showed that it was within the standard deviation, and docetaxel was continued. Nonetheless, after 11 courses of docetaxel, PSA increased to 4.1 ng/ml, and the disease was thought to have progressed, with peripheral neuropathy appearing as a side effect, so cabazitaxel administration was initiated.

Subjective Heading

Simultaneously, symptoms of back pain associated with sacral metastasis worsened, and stereotactic body radiation therapy (SBRT) was performed. After five courses of therapy, the PSA level dropped to 3.2 ng/ml; however, contrast-enhanced CT scan findings revealed liver metastasis, and the disease was deemed to have progressed once more. Metastasis was found primarily in the pelvis and vertebrae, with no metastasis found in the skull. Furthermore, carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) levels were elevated to 201.5 and 47.2 ng/ml, indicating a neuroendocrine tumour, respectively. At the same time, symptoms of hearing loss appeared, and the patient was referred to our hospital's Department of Otorhinolaryngology for a thorough examination, where CT findings revealed

Discussion

A histological examination of the tumour in the external auditory canal revealed that it was an adenocarcinoma metastasis of prostate

*Corresponding author: Naoki Akagi, Department of Urology, Takarazuka City Hospital, Japan, E-mail: naoakivuyi@gmail.com

Received: 04-Aug-2022, Manuscript No: jcmp-22-70992, **Editor assigned:** 06-Aug-2022, PreQC No: jcmp-22-70992 (PQ), **Reviewed:** 20-Aug-2022, QC No: jcmp-22-70992, **Revised:** 22-Aug-2022, Manuscript No: jcmp-22-70992 (R), **Published:** 29-Aug-2022; DOI: 10.4172/jcmp.1000126

Citation: Akagi N (2022) Case Report of Castration-Resistant Prostate Cancer with Metastasis to the External Auditory Canal. *J Cell Mol Pharmacol* 6: 126.

Copyright: © 2022 Akagi N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

the main complaint. Two pathways, vascular and perineural, have been identified for direct metastasis to an external auditory canal, and those in combination can also be affected. 4 A standard treatment protocol has yet to be established due to the small number of reports of prostate cancer metastasis to an external auditory canal. A report presented by another hospital's otorhinolaryngology department in Japan stated that a patient with facial nerve palsy associated with temporal bone metastasis from prostate cancer had hearing loss that improved after radiation therapy. 5 In the case of the current patient, we considered SBRT after consulting with the Department of Otorhinolaryngology at our hospital. However, by that time, his general condition had deteriorated, making it difficult to treat him. Important to consider metastasis to the external auditory canal as a possibility and an otolaryngologist should be consulted to perform an imaging study and then SBRT considered as an option.

Conclusion

Two pathways have been identified for direct metastasis to an external auditory canal: vascular and perineural, and those in combination can also be affected. 4 A standard treatment protocol has yet to be established due to the small number of reports of prostate cancer metastasis to the external auditory canal. According to a report presented by another hospital's otorhinolaryngology department in Japan, a patient with facial nerve palsy associated with temporal bone metastasis from prostate cancer had hearing loss that improved after radiation therapy. In the case of the current patient, consultation with our hospital's Department of Otorhinolaryngology led us to consider SBRT as a possible treatment option. However, by that time, his overall condition had deteriorated, making it difficult to treat him.

Simultaneously, symptoms of back pain associated with sacral metastasis worsened, and stereotactic body radiation therapy (SBRT) was performed. After five courses of therapy, the PSA level dropped to 3.2 ng/ml; however, contrast-enhanced CT scan findings revealed liver metastasis, and the disease was deemed to have progressed once more. Metastasis was found primarily in the pelvis and vertebrae, with no metastasis found in the skull. Furthermore, carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) levels were elevated to 201.5 and 47.2 ng/ml, indicating a neuroendocrine tumour, respectively. At the same time, symptoms of hearing loss appeared, and the patient was referred to our hospital's Department of Otorhinolaryngology for a thorough examination. A mass lesion in the left external auditory canal was discovered using CT imaging. A histological examination of the tumour in the external auditory canal revealed that it was an adenocarcinoma metastasis of prostate cancer (Fig. 2). Because neuroendocrine degeneration was suspected, prostate and liver biopsy procedures were repeated, and histological results from those specimens confirmed that the lesion was an adenocarcinoma. Following that, the patient complained of headaches and facial paralysis, and magnetic resonance imaging (MRI) results confirmed facial nerve compression, as well as extension to the inner ear and metastasis in the cerebral concha. SBRT was considered as a treatment option for metastasis to the external auditory canal once more. However, due to the patient's decreased performance status, it was decided to perform follow-up examinations, and he was primarily treated with palliative therapy. The patient died two weeks after being diagnosed with ear canal metastasis, and a PSA level of 3.7 ng/ml was found.

Two pathways, vascular and perineural, have been identified for direct metastasis to an external auditory canal, and those in combination can also be affected. 4 A standard treatment protocol has

yet to be established due to the small number of reports of prostate cancer metastasis to an external auditory canal. A report presented by another hospital's otorhinolaryngology department in Japan stated that a patient with facial nerve palsy associated with temporal bone metastasis from prostate cancer had hearing loss that improved after radiation therapy. 5 In terms of the Consultation with our hospital's Department of Otorhinolaryngology led us to consider SBRT as a potential treatment option for the current patient. However, by that time, his general condition had deteriorated, making aggressive treatment difficult. Although this is a rare case, if symptoms such as hearing loss or facial nerve palsy appear during prostate cancer treatment, it is important to consider metastasis to the external auditory canal as a possibility, and an otolaryngologist should be consulted to perform an imaging study before SBRT is considered.

Acknowledgements

I would like to thank my Professor for his support and encouragement.

Conflict of Interest

The authors declare that they are no conflict of interest.

References

1. Acorci MJ, Dias LA (2009) Inhibition of human neutrophil apoptosis by *Paracoccidioides brasiliensis* Role of interleukin. *J Immunol* 69: 73-79.
2. Akgu C, Edwards SW (2003) Regulation of neutrophil apoptosis via death receptors. *Cell Mol Life Sci* 60: 2402-2408.
3. Alder JD, Daugherty N, Harris ON (1989) Phagocytosis of *Treponema pallidum*. *J Infect Dis* 160: 289-297.
4. Alderete JF, Baseman JB (1986) Surface-associated host proteins on virulent *Treponema pallidum*. *Infect Immun* 26: 1048-1105.
5. Baker SA, Zander SA (1992) Macrophage-mediated killing of opsonized *Treponema pallidum*. *J Infect Dis* 165: 69-74.
6. Acorci MJ, Dias LA, Golim MA (2009) Inhibition of human neutrophil apoptosis by *Paracoccidioides brasiliensis* Role of interleukin 8. *Scand J Immunol* 69: 73-79.
7. Akgul C, Edwards SW (2003) Regulation of neutrophil apoptosis via death receptors. *Cell Mol Life Sci* 60: 2402-2408.
8. Alderete JB, Baseman NJ (1979) Surface-associated host proteins on virulent *Treponema pallidum*. *Infect Immun* 26: 1048-1056.
9. Baker AS (1992) Macrophage-mediated killing of opsonized *Treponema pallidum*. *J Infect Dis* 165: 69-74.
10. Baseman JB, Nichols JC, Rumpp JW (2007) Assessment and interpretation of cytometry. *Appl Environ Microbiol* 73: 3283-3290.
11. Byrne R, Noritz G (2017) Implementation of early diagnosis and intervention guidelines for cerebral palsy in a high-risk infant follow-up clinic. *Pediatr Neurol* 76: 66-71.
12. Granild JB (2015) Predictors for early diagnosis of cerebral palsy from national registry. *dataDev Med Child Neuro* 57 (10): 931-935.
13. Novak C, Morgan L, Adde J (2017) Early accurate diagnosis and early intervention in cerebral palsy advances in diagnosis and treatment. *JAMA Pediatr* 171 (9): 897-907.
14. Morgan C, Crowle C (2016) Assessment for diagnostic accuracy of detecting cerebral palsy early in an Australian context. *J Paediatr Child Health* 52 (1): 54-59.
15. Bosanquet M, Copeland L (2013) A systematic review of tests to predict cerebral palsy in young children. *Dev Med Child Neurol* 55 (5): 418-426.